Dr. Baltimore Says It's Time to Revive AIDS Vaccine Ideas

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 6 No 7
Volume 6
Issue 7

BETHESDA, Md--It's time to recycle some old ideas in AIDS vaccines, Nobel laureate David Baltimore, PhD, told the Advisory Committee to the Director of the National Institutes of Health.

BETHESDA, Md--It's time to recycle some old ideas in AIDS vaccines,Nobel laureate David Baltimore, PhD, told the Advisory Committee to theDirector of the National Institutes of Health.

Dr. Baltimore, currently at the Massachusetts Institute of Technologyand president-elect of the California Institute of Technology, chairs anadvisory committee named by NIH director Harold Varmus, MD, to devise acomprehensive national research program to develop an effective AIDS vaccine.Looking at the candidate AIDS vaccines tested so far, Dr. Baltimore expressedhis concern that none of them may be able to effectively prevent the disease.

The growing understanding of how the human immunodeficiency virus changesand functions has led him to conclude that scientists need to reconsidera variety of vaccine approaches discarded earlier, he said. These includekilled viruses, virus-like particles, protein-based vaccines, naked DNA,and live, attenuated vaccines.

Because a live vaccine would involve actually infecting people, albeitwith a crippled virus, "that concept is appropriately worrisome,"Dr. Baltimore acknowledged. Nonetheless, that approach could be the mosteffective.

"What the committee is doing is trying to suggest new scientificinitiatives," he said. "What we'd most like to do is get newvaccine concepts under testing." However, he emphasized that an AIDSvaccine will take years to perfect: "It is intrinsic to the developmentthat it takes a long time."

Dr. Baltimore said the AIDS vaccine committee has held a series of regionalworkshops intended to generate new ideas and bring new minds into the effort."We would like to encourage people who have not worked on HIV to comeinto the field," he said.

Related Videos
Barbara Smith, MD, PhD, spoke about the potential use of pegulicianine-guided breast cancer surgery based on reports from the phase 3 INSITE trial.
Patient-reported symptoms following surgery appear to improve with the use of perioperative telemonitoring, says Kelly M. Mahuron, MD.
Treatment options in the refractory setting must improve for patients with resected colorectal cancer peritoneal metastasis, says Muhammad Talha Waheed, MD.
Karine Tawagi, MD, and Sia Daneshmand, MD, with the Oncology Brothers presenting slides
Karine Tawagi, MD, and Sia Daneshmand, MD, with the Oncology Brothers presenting slides
Karine Tawagi, MD, and Sia Daneshmand, MD, with the Oncology Brothers presenting slides
Karine Tawagi, MD, and Sia Daneshmand, MD, with the Oncology Brothers presenting slides
Related Content